Reaction

Hyperchlorhydria reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,866 reports · 73 co-occurring drugs

As of the last recalculation, Hyperchlorhydria appears in 5,866 FAERS reports alongside 73 co-occurring drug terms. The strongest observed disproportionality signal is DEXLANSOPRAZOLE (PRR 73.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Dexlansoprazole	755	73.6	74.9
Lansoprazole	2,028	61.2	61.9
Esomeprazole Magnesium	1,959	44.1	44.5
Omeprazole Magnesium	2,758	40.4	40.7
Pantoprazole Sodium	1,111	32.6	32.8
Ado-Trastuzumab Emtansine	25	10.6	10.6
Exenatide	114	7.8	7.8
Gentamicin	19	5.2	5.2
Mupirocin	19	5.0	5.0
Mupirocin Calcium	19	4.9	4.9
Gentamicin Sulfate	19	4.3	4.3
Rabeprazole Sodium	32	4.2	4.2
Esomeprazole Magnesium Capsule, Delayed Release	17	4.2	4.2
Esomeprazole Magnesium Delayed Release Capsules	17	4.2	4.2
Esomeprazole Magnesium Dihydrate	17	4.1	4.2
Liraglutide	57	4.1	4.1
Cimetidine	11	4.1	4.1
Pertuzumab	30	3.9	3.9
Hyoscyamine Sulfate	10	3.9	3.9
Esomeprazole	64	3.7	3.7
Omeprazole	343	3.7	3.7
Amlodipine Besylate And Valsartan	11	3.5	3.5
Insulin Glulisine	10	3.5	3.5
Sunitinib Malate	37	3.4	3.4
Dicyclomine Hydrochloride	13	3.2	3.2
Sucralfate	20	3.0	3.0
Crizotinib	10	2.8	2.8
Famotidine	84	2.6	2.6
Pirfenidone	28	2.4	2.4
Glipizide	40	2.3	2.3
Meropenem	21	2.3	2.3
Sitagliptin And Metformin Hydrochloride	14	2.3	2.3
Nilotinib	19	2.3	2.3
Metformin Hcl	35	2.3	2.3
Piperacillin And Tazobactam	8	2.2	2.2
Dimethyl Fumarate	75	2.2	2.2
Niraparib	13	2.1	2.1
Filgrastim	22	2.1	2.1
Dulaglutide	51	2.0	2.1
Piperacillin Sodium,Tazobactam Sodium	15	2.0	2.0
Nicotine Polacrilex	20	1.9	1.9
Pazopanib Hydrochloride	14	1.8	1.8
Trastuzumab	35	1.8	1.8
Diroximel Fumarate	6	1.8	1.8
Peginterferon Alfa-2A	25	1.6	1.6
Alpelisib	4	1.6	1.6
Ribavirin	27	1.5	1.5
Docetaxel Anhydrous	28	1.5	1.5
Docetaxel	28	1.5	1.5
Sofosbuvir	8	1.4	1.4
Canagliflozin	12	1.4	1.4
Fam-Trastuzumab Deruxtecan-Nxki	4	1.4	1.4
Dronedarone	4	1.4	1.4
Vedolizumab	33	1.4	1.4
Dasatinib	14	1.3	1.3
Palbociclib	35	1.3	1.3
Sevelamer Carbonate	4	1.2	1.2
Dabigatran Etexilate Mesylate	25	1.2	1.2
Dabigatran Etexilate	26	1.2	1.2
Olaparib	7	1.2	1.2
Ledipasvir And Sofosbuvir	6	1.1	1.1
Enzalutamide	18	1.1	1.1
Varenicline Tartrate	24	1.1	1.1
Patiromer	4	1.0	1.0
Trifluridine And Tipiracil	3	1.0	1.0
Orlistat	7	1.0	1.0
Tafamidis	3	0.9	0.9
Cabozantinib	12	0.9	0.9
Elexacaftor, Tezacaftor, And Ivacaftor	3	0.9	0.9
Nirmatrelvir And Ritonavir	13	0.9	0.9
Ranitidine Hydrochloride	12	0.8	0.8
Tirzepatide	28	0.6	0.6
Apremilast	22	0.5	0.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.